South African health authorities raided a Pretoria-based company this month to seize unregistered and illegal injectable weight-loss products [1].
The crackdown targets the illicit manufacture and distribution of GLP-1-based drugs, which can pose significant public health risks when produced without regulatory oversight [1].
The South African Health Products Regulatory Authority (SAHPRA) conducted the operation in coordination with the South African Pharmacy Council [1]. The raid focused on a facility in Gauteng Province that was producing injectables such as semaglutide and tirzepatide [1, 2]. These medications are widely known for weight loss but require strict registration and quality control to ensure patient safety [2].
According to SAHPRA, the products were being marketed illegally for weight-loss purposes [1]. The agency said that the manufacturing and sale of these unregistered drugs bypass critical safety protocols, a practice that can lead to contaminated or improperly dosed medication [2].
Dr. Boitumelo S, CEO of SAHPRA, said the action was necessary to protect the public from unregulated medical products [1]. The agency said that only registered medicines should be administered to patients to avoid adverse health outcomes [1].
The operation is part of a broader effort by the South African government to curb the rise of "black market" pharmaceuticals [2]. Authorities are now investigating the distribution networks used by the Pretoria company to sell these injectables to consumers [1, 2].
“The products were unregistered and being marketed illegally for weight‑loss purposes”
This raid highlights the growing global challenge of regulating GLP-1 agonists as demand for weight-loss medications surges. When these drugs are produced in unregistered facilities, they lack the sterility and dosage precision required for injectables, increasing the risk of infections or metabolic emergencies for users.
